Oxytocin (medication)

From Wikipedia, the free encyclopedia
  (Redirected from Pitocin)
Jump to: navigation, search
Oxytocin
Oxytocin with labels.png
OxitocinaCPK3D.png
Clinical data
Pronunciation /ˌɒksɪˈtsɪn/
Trade names Pitocin, Syntocinon, others
AHFS/Drugs.com Monograph
Pregnancy
category
  • AU: A
Routes of
administration
Intranasal, IV, IM
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding 30%
Metabolism Liver and elsewhere (via oxytocinases)
Biological half-life 1–6 min (IV)
~2 h (intranasal)[1][2]
Excretion Biliary and kidney
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
Chemical and physical data
Formula C43H66N12O12S2
Molar mass 1007.19 g/mol
3D model (JSmol)
  (verify)

Oxytocin, sold under the brand name Pitocin among others, is a medication made from the peptide oxytocin.[3][4] As a medication, it is used to cause contraction of the uterus in order to start labor, increase the speed of labor, and to stop bleeding following delivery.[3] For this purpose, it is given by injection either into a muscle or into a vein.[3]

The use of oxytocin as a medication can result in excessive contraction of the uterus that can risk the health of the baby.[3] Common side effects in the mother include nausea and a slow heart rate.[3] Serious side effects include rupture of the uterus and with excessive dose, water intoxication.[3] Allergic reactions including anaphylaxis may also occur.[3]

Oxytocin was discovered in 1952.[5] It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.[6] As of 2014, the wholesale cost in the developing world is US$0.1–0.56 per dose.[7]

Medical uses[edit]

Contraindications[edit]

Oxytocin injection (synthetic) is contraindicated in any of the following conditions:[11]

Side effects[edit]

Oxytocin is relatively safe when used at recommended doses, and side effects are uncommon.[12] The following maternal events have been reported:[12]

Excessive dosage or long-term administration (over a period of 24 hours or longer) have been known to result in tetanic uterine contractions, uterine rupture, postpartum hemorrhage, and water intoxication, sometimes fatal.

During pregnancy, increased uterine motility has led to decreased heart rate, cardiac arrhythmia, seizures, brain damage, and death in the fetus or neonate:[12]

Certain learning and memory functions are impaired by centrally administered oxytocin.[13] Also, systemic oxytocin administration can impair memory retrieval in certain aversive memory tasks.[14] However, oxytocin does seem to facilitate learning and memory specifically for social information. Healthy males administered intranasal oxytocin show improved memory for human faces, in particular happy faces.[15][16]

Pharmacokinetics[edit]

Routes of administration[edit]

A bag of oxytocin for intravenous infusion

1 IU of oxytocin is the equivalent of about 2 μg or mcg of pure peptide.

History[edit]

Its uterine-contracting properties were discovered by British pharmacologist Sir Henry Hallett Dale in 1906.[23] And its milk ejection property was described by Ott and Scott in 1910[24] and by Schafer and Mackenzie in 1911.[25]

Oxytocin became the first polypeptide hormone to be sequenced[26] or synthesized.[27][28] Du Vigneaud was awarded the Nobel Prize in 1955 for his work.[29]

Etymology[edit]

The word oxytocin was coined from the term oxytocic. Greek ὀξύς, oxys, and τόκος, tokos, meaning "quick birth").

Society and culture[edit]

Legality[edit]

Oxytocin is not scheduled as a narcotic.[citation needed]

Counterfeits[edit]

Oxytocin is marketed as a pheromone. Oxytocin in spray form is sold under the brands Attrakt and Connekt. Oxytocin is not absorbed into the skin when used topically,[citation needed] however it may be inhaled in a manner similar to perfume applied to skin. Oxytocin sprays for insufflation are also sold but often with little or no oxytocin at all.[citation needed]

In African countries some oxytocin products were found to be counterfeit medications.[30][31]

Research[edit]

The trust-inducing property of oxytocin might help those with social anxiety and depression,[32] anxiety, fear, and social dysfunctions, such as generalized anxiety disorder, posttraumatic stress disorder, and social anxiety disorder, as well as autism and schizophrenia, among others.[33][34] However, in one meta-analysis only autism spectrum disorder showed a significant combined effect size.[35]

People using oxytocin show improved recognition for positive social cues over threatening social cues [36][37] and improved recognition of fear.[38] However, oxytocin has also the potential for being abused in confidence tricks.[39]

See also[edit]

References[edit]

  1. ^ a b Weisman O, Zagoory-Sharon O, Feldman R (September 2012). "Intranasal oxytocin administration is reflected in human saliva". Psychoneuroendocrinology. 37 (9): 1582–6. doi:10.1016/j.psyneuen.2012.02.014. PMID 22436536. 
  2. ^ a b Huffmeijer R, Alink LR, Tops M, Grewen KM, Light KC, Bakermans-Kranenburg MJ, Ijzendoorn MH (2012). "Salivary levels of oxytocin remain elevated for more than two hours after intranasal oxytocin administration". Neuro Endocrinology Letters. 33 (1): 21–5. PMID 22467107. 
  3. ^ a b c d e f g h i "Oxytocin". The American Society of Health-System Pharmacists. Archived from the original on 20 May 2015. Retrieved 1 June 2015. 
  4. ^ The Oxford Handbook of Prosocial Behavior. Oxford University Press. 2015. p. 354. ISBN 978-0-19-539981-3. Archived from the original on 2017-08-01. 
  5. ^ Corey E (2012). "Oxytocin". Molecules and Medicine. John Wiley & Sons. ISBN 978-1-118-36173-3. Archived from the original on 2015-12-22. 
  6. ^ "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016. 
  7. ^ "Oxytocin". International Drug Price Indicator Guide. Retrieved 20 December 2015. 
  8. ^ Budden A, Chen LJ, Henry A (Oct 9, 2014). "High-dose versus low-dose oxytocin infusion regimens for induction of labour at term". The Cochrane Database of Systematic Reviews. 10 (10): CD009701. doi:10.1002/14651858.CD009701.pub2. PMID 25300173. 
  9. ^ Fewtrell MS, Loh KL, Blake A, Ridout DA, Hawdon J (May 2006). "Randomised, double blind trial of oxytocin nasal spray in mothers expressing breast milk for preterm infants". Archives of Disease in Childhood: Fetal and Neonatal Edition. 91 (3): F169–74. doi:10.1136/adc.2005.081265. PMC 2672698Freely accessible. PMID 16223754. 
  10. ^ "Oxytocin use while Breastfeeding". Drugs.com. Archived from the original on 2016-12-15. 
  11. ^ "Archived copy". Archived from the original on 2016-12-21. Retrieved 2016-12-16. 
  12. ^ a b c "Pitocin (drug label for professionals)". Rx List. WebMD. Archived from the original on 2011-04-15. Retrieved 2010-09-09. 
  13. ^ Gimpl G, Fahrenholz F (April 2001). "The oxytocin receptor system: structure, function, and regulation". Physiological Reviews. 81 (2): 629–83. PMID 11274341. 
  14. ^ de Oliveira LF, Camboim C, Diehl F, Consiglio AR, Quillfeldt JA (January 2007). "Glucocorticoid-mediated effects of systemic oxytocin upon memory retrieval". Neurobiology of Learning and Memory. 87 (1): 67–71. doi:10.1016/j.nlm.2006.05.006. PMID 16997585. 
  15. ^ Guastella AJ, Mitchell PB, Mathews F (August 2008). "Oxytocin enhances the encoding of positive social memories in humans". Biological Psychiatry. 64 (3): 256–8. doi:10.1016/j.biopsych.2008.02.008. PMID 18343353. 
  16. ^ Rimmele U, Hediger K, Heinrichs M, Klaver P (January 2009). "Oxytocin makes a face in memory familiar". The Journal of Neuroscience. 29 (1): 38–42. doi:10.1523/JNEUROSCI.4260-08.2009. PMID 19129382. 
  17. ^ Baribeau DA, Anagnostou E (2015). "Oxytocin and vasopressin: linking pituitary neuropeptides and their receptors to social neurocircuits". Frontiers in Neuroscience. 9: 335. doi:10.3389/fnins.2015.00335. PMC 4585313Freely accessible. PMID 26441508. 
  18. ^ Mehta AC (1986). "Buccal and oral drugs: induction of labour". Acta Chirurgica Hungarica. 27 (3): 157–63. PMID 3469841. 
  19. ^ De Groot AN, Vree TB, Hekster YA, Pesman GJ, Sweep FC, Van Dongen PJ, Van Roosmalen J (1995). "Bioavailability and pharmacokinetics of sublingual oxytocin in male volunteers". The Journal of Pharmacy and Pharmacology. 47 (7): 571–5. doi:10.1111/j.2042-7158.1995.tb06716.x. PMID 8568623. 
  20. ^ Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter 7: Neuropeptides". In Sydor A, Brown RY. Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (2nd ed.). New York: McGraw-Hill Medical. ISBN 978-0-07-148127-4. Oxytocin can be delivered to humans via nasal spray following which it crosses the blood–brain barrier. ... In a double-blind experiment, oxytocin spray increased trusting behavior compared to a placebo spray in a monetary game with real money at stake. 
  21. ^ McGregor IS, Callaghan PD, Hunt GE (May 2008). "From ultrasocial to antisocial: a role for oxytocin in the acute reinforcing effects and long-term adverse consequences of drug use?". British Journal of Pharmacology. 154 (2): 358–68. doi:10.1038/bjp.2008.132. PMC 2442436Freely accessible. PMID 18475254. Recent studies also highlight remarkable anxiolytic and prosocial effects of intranasally administered OT in humans, including increased ‘trust’, decreased amygdala activation towards fear-inducing stimuli, improved recognition of social cues and increased gaze directed towards the eye regions of others (Kirsch et al., 2005; Kosfeld et al., 2005; Domes et al., 2006; Guastella et al., 2008). 
  22. ^ Lee SY, Lee AR, Hwangbo R, Han J, Hong M, Bahn GH (2015). "Is Oxytocin Application for Autism Spectrum Disorder Evidence-Based?". Experimental Neurobiology. 24 (4): 312–24. doi:10.5607/en.2015.24.4.312. PMC 4688331Freely accessible. PMID 26713079. 
  23. ^ Dale HH (May 1906). "On some physiological actions of ergot". The Journal of Physiology. 34 (3): 163–206. doi:10.1113/jphysiol.1906.sp001148. PMC 1465771Freely accessible. PMID 16992821. 
  24. ^ Ott I, Scott JC (1910). "The Action of Infundibulum upon Mammary Secretion". Proc Soc Exp Biol. 8: 48–49. 
  25. ^ Schafer EA, Mackenzie K (July 1911). "The Action of Animal Extracts on Milk Secretion". Proceedings of the Royal Society B. 84 (568): 16–22. doi:10.1098/rspb.1911.0042. 
  26. ^ Du Vigneaud V, Ressler C, Trippett S (December 1953). "The sequence of amino acids in oxytocin, with a proposal for the structure of oxytocin". The Journal of Biological Chemistry. 205 (2): 949–57. PMID 13129273. 
  27. ^ du Vigneaud V, Ressler C, Swan JM, Roberts CW, Katsoyannis PG, Gordon S (1953). "The synthesis of an octapeptide amide with the hormonal activity of oxytocin". J. Am. Chem. Soc. 75 (19): 4879–80. doi:10.1021/ja01115a553. 
  28. ^ du Vigneaud V, Ressler C, Swan JM, Roberts CW, Katsoyannis PG (June 1954). "The synthesis of oxytocin". J. Am. Chem. Soc. 76 (12): 3115–3121. doi:10.1021/ja01641a004. 
  29. ^ Du Vigneaud V (June 1956). "Trail of sulfur research: from insulin to oxytocin". Science. 123 (3205): 967–74. doi:10.1126/science.123.3205.967. PMID 13324123. 
  30. ^ Torloni MR, Gomes Freitas C, Kartoglu UH, Metin Gülmezoglu A, Widmer M (December 2016). "Quality of oxytocin available in low- and middle-income countries: a systematic review of the literature". BJOG: an International Journal of Obstetrics and Gynaecology. 123 (13): 2076–2086. doi:10.1111/1471-0528.13998. PMID 27006180. 
  31. ^ Stanton C, Koski A, Cofie P, Mirzabagi E, Grady BL, Brooke S (2012). "Uterotonic drug quality: an assessment of the potency of injectable uterotonic drugs purchased by simulated clients in three districts in Ghana". BMJ Open. 2 (3): e000431. doi:10.1136/bmjopen-2011-000431. PMC 3346944Freely accessible. PMID 22556159. 
  32. ^ Hurlemann R, Patin A, Onur OA, Cohen MX, Baumgartner T, Metzler S, Dziobek I, Gallinat J, Wagner M, Maier W, Kendrick KM (April 2010). "Oxytocin enhances amygdala-dependent, socially reinforced learning and emotional empathy in humans". The Journal of Neuroscience. 30 (14): 4999–5007. doi:10.1523/JNEUROSCI.5538-09.2010. PMID 20371820. 
  33. ^ Cochran DM, Fallon D, Hill M, Frazier JA (2013). "The role of oxytocin in psychiatric disorders: a review of biological and therapeutic research findings". Harvard Review of Psychiatry. 21 (5): 219–47. doi:10.1097/HRP.0b013e3182a75b7d. PMC 4120070Freely accessible. PMID 24651556. 
  34. ^ Neumann ID, Slattery DA (2016). "Oxytocin in General Anxiety and Social Fear: A Translational Approach". Biological Psychiatry. 79 (3): 213–21. doi:10.1016/j.biopsych.2015.06.004. PMID 26208744. 
  35. ^ Bakermans-Kranenburg MJ, van I Jzendoorn MH (2013). "Sniffing around oxytocin: review and meta-analyses of trials in healthy and clinical groups with implications for pharmacotherapy". Translational Psychiatry. 3 (5): e258. doi:10.1038/tp.2013.34. PMC 3669921Freely accessible. PMID 23695233. 
  36. ^ Unkelbach C, Guastella AJ, Forgas JP (November 2008). "Oxytocin selectively facilitates recognition of positive sex and relationship words". Psychological Science. 19 (11): 1092–4. doi:10.1111/j.1467-9280.2008.02206.x. PMID 19076479. 
  37. ^ Marsh AA, Yu HH, Pine DS, Blair RJ (April 2010). "Oxytocin improves specific recognition of positive facial expressions". Psychopharmacology. 209 (3): 225–32. doi:10.1007/s00213-010-1780-4. PMID 20186397. 
  38. ^ Fischer-Shofty M, Shamay-Tsoory SG, Harari H, Levkovitz Y (2010). "The effect of intranasal administration of oxytocin on fear recognition". Neuropsychologia. 48 (1): 179–84. doi:10.1016/j.neuropsychologia.2009.09.003. PMID 19747930. 
  39. ^ Tennison MN, Moreno JD (2012). "Neuroscience, ethics, and national security: the state of the art". PLOS Biology. 10 (3): e1001289. doi:10.1371/journal.pbio.1001289. PMC 3308927Freely accessible. PMID 22448146. 
  40. ^ Bartz JA, Hollander E (2008). "Oxytocin and experimental therapeutics in autism spectrum disorders". Progress in Brain Research. Progress in Brain Research. 170: 451–62. doi:10.1016/S0079-6123(08)00435-4. ISBN 978-0-444-53201-5. PMID 18655901. 
  41. ^ Wudarczyk OA, Earp BD, Guastella A, Savulescu J (2013). "Could intranasal oxytocin be used to enhance relationships? Research imperatives, clinical policy, and ethical considerations". Current Opinion in Psychiatry. 26 (5): 474–84. doi:10.1097/YCO.0b013e3283642e10. PMC 3935449Freely accessible. PMID 23880593.